3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Chronic Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gray, JA; Gray, NS; Kerwin, RW; Pilowsky, LS | 1 |
| Holzmann, T; Hör, G; Maul, FD; Pflug, B; Schreiner, M; Volk, S; Weppner, M | 1 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Chronic Illness
| Article | Year |
|---|---|
Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.
Topics: Adolescent; Adult; Attention; Basal Ganglia; Benzamides; Chronic Disease; Contrast Media; Corpus Striatum; Female; Humans; Male; Neural Inhibition; Neuropsychological Tests; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 1995 |
Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Chronic Disease; Contrast Media; Dopamine Antagonists; Female; Frontal Lobe; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1994 |